AbbVie vs. Hetero USA: Consent Judgment Blocks Generic Upadacitinib

Case Overview

In a swift and decisive resolution, AbbVie, Inc. secured a consent judgment against Hetero USA, Inc. in the U.S. District Court for the District of Delaware, permanently enjoining Hetero from commercializing generic versions of RINVOQ® (upadacitinib) extended-release tablets in 15 mg, 30 mg, and 45 mg dosages. The case—AbbVie, Inc. v. Hetero USA, Inc., No. 1:25-cv-00190—closed on August 4, 2025, just 171 days after filing, a timeline that reflects the efficiency of negotiated ANDA litigation resolutions in the pharmaceutical patent space.

The case centers on Hetero’s Abbreviated New Drug Application (ANDA No. 218859), which the court formally adjudicated as an act of infringement under 35 U.S.C. § 271(e)(2)(A) across four AbbVie patents covering upadacitinib formulation technology. For pharma IP professionals, patent litigators, and R&D teams navigating the increasingly competitive JAK inhibitor landscape, this outcome offers critical strategic intelligence about how branded pharmaceutical companies protect blockbuster assets against generic challengers.

The Parties

The Patents at Issue

This landmark case involved four AbbVie patents covering upadacitinib extended-release formulation technology:

• • U.S. Patent No. 11,564,922 — Extended-release formulation technology
• • U.S. Patent No. 11,607,411 — Extended-release formulation technology
• • U.S. Patent No. 10,202,393 — Active compound and formulation methods
• • U.S. Patent No. 12,134,621 — Extended-release delivery mechanisms

The Accused Products

Hetero’s ANDA No. 218859 sought FDA approval for generic upadacitinib extended-release tablets in all three commercially significant dosage strengths (15 mg, 30 mg, and 45 mg)—a direct challenge to AbbVie’s full RINVOQ® product line.

Legal Representation

Plaintiff AbbVie was represented by Jeremy A. Tigan and Megan Elizabeth Dellinger of Morris, Nichols, Arsht & Tunnell LLP.

Defendant Hetero USA assembled a seven-attorney team from Greenberg Traurig PA, including Scott J. Bornstein, Anne M. Rock, Benjamin J. Schladweiler, Brian J. Prew, Giancarlo L. Scaccia, Jonathan R. Wise, and Renee Mosley Delcollo.

Litigation Timeline & Procedural History

AbbVie filed suit on February 14, 2025, in the District of Delaware—the preeminent venue for pharmaceutical patent litigation under the Hatch-Waxman Act. Delaware’s established precedent, judicial efficiency, and familiarity with ANDA disputes make it the strategic default forum for branded pharmaceutical plaintiffs.

The case was presided over by Chief Judge Maryellen Noreika, a respected jurist with a substantial pharmaceutical patent docket and a reputation for maintaining efficient case management in complex IP matters.

The 171-day resolution—without trial—reflects a negotiated consent judgment, bypassing claim construction, fact discovery, and expert phases entirely. For context, contested Hatch-Waxman trials in Delaware frequently extend 18–36 months. This accelerated closure signals that the parties reached a commercial accommodation, likely including a confidential entry date for Hetero’s generic product tied to AbbVie’s patent expiration or other licensing terms not disclosed in the public record.

The Verdict & Legal Analysis

Outcome

The court entered a Stipulated Consent Judgment and Permanent Injunction on August 4, 2025. The order contains several legally significant provisions:

Infringement admitted: The court formally decreed that “the filing of ANDA No. 218859 was an act of infringement of the Asserted Patents under 35 U.S.C. § 271(e)(2)(A).” This statutory infringement provision—the cornerstone of Hatch-Waxman enforcement—deems ANDA filing itself an infringing act, enabling patent holders to litigate before any generic product reaches market.

Permanent injunction granted: Hetero, its officers, agents, and affiliates are enjoined from manufacturing, using, offering to sell, selling, or importing the accused generic upadacitinib tablets in the United States during the life of the asserted patents, including any patent term extensions and pediatric exclusivity periods.

No damages disclosed: Consistent with negotiated ANDA resolutions, no monetary damages were awarded or disclosed. The commercial resolution terms—if any authorized entry date was agreed upon—remain confidential.

All other claims dismissed without prejudice: Hetero’s counterclaims (likely invalidity and non-infringement challenges) were dismissed without prejudice, preserving the ability to re-litigate patent validity in a future action involving different products or different ANDA numbers.

Verdict Cause Analysis

The infringement action was premised on 35 U.S.C. § 271(e)(2)(A), which creates a cause of action upon ANDA filing for a patented drug before patent expiration. No validity or infringement findings on the merits were litigated; the stipulated nature of the judgment means AbbVie’s patents were not formally construed or challenged through the judicial process in this action.

The dismissal of counterclaims without prejudice is a strategically meaningful term. Hetero preserves its right to challenge AbbVie’s patents in future proceedings—either through a new ANDA for a different product, an IPR petition at the USPTO, or a declaratory judgment action. This clause protects Hetero’s long-term litigation optionality while resolving the immediate commercial dispute.

Legal Significance

This case exemplifies the “30-month stay” dynamic inherent in Hatch-Waxman litigation. By filing suit within 45 days of receiving Paragraph IV certification notice, AbbVie automatically triggered the 30-month FDA approval stay for Hetero’s ANDA. The consent judgment entered before that stay expired effectively extends market exclusivity without requiring AbbVie to win on the merits—a significant strategic outcome.

The four-patent assertion across compound, formulation, and delivery mechanism claims reflects portfolio layering, a standard practice for pharmaceutical innovators seeking redundant protection against design-arounds.

Industry & Competitive Implications

The upadacitinib patent dispute reflects intensifying generic competition across the JAK inhibitor class. As RINVOQ® continues expanding indications, its commercial significance to AbbVie’s post-HUMIRA revenue strategy makes aggressive patent enforcement economically imperative.

For the broader pharmaceutical IP landscape, this case reinforces Delaware’s dominance as the preferred Hatch-Waxman venue and demonstrates how branded companies use multi-patent portfolios to achieve negotiated resolutions that effectively extend market exclusivity without exposing core patents to merits-based invalidity rulings.

The without-prejudice dismissal of Hetero’s counterclaims means this dispute is not fully resolved from a patent validity standpoint. Other generic manufacturers holding Paragraph IV certifications against RINVOQ® patents—or those considering ANDA filings—should monitor whether Hetero pursues IPR proceedings at the USPTO against any of the four asserted patents, as successful IPR outcomes could open the generic pathway for multiple challengers simultaneously.

Licensing terms, if any authorized entry date was agreed upon, could also reshape competitive dynamics in the upadacitinib market upon disclosure or expiration of confidentiality obligations.

❔ Frequently Asked Questions

What patents were involved in AbbVie v. Hetero USA?

Four patents were asserted: U.S. Patent Nos. 11,564,922; 11,607,411; 10,202,393; and 12,134,621, covering upadacitinib (RINVOQ®) extended-release tablet formulations.

What was the basis for the outcome in this case?

The court entered a stipulated consent judgment finding that Hetero’s ANDA No. 218859 filing constituted patent infringement under 35 U.S.C. § 271(e)(2)(A), with a permanent injunction blocking generic upadacitinib commercialization during the patents’ remaining terms.

How might this case affect upadacitinib patent litigation?

The without-prejudice dismissal of invalidity counterclaims leaves AbbVie’s patents vulnerable to future IPR challenges. Generic competitors should track PTAB filings against the four asserted patents closely.